These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Sense and nonsense of post-authorization surveillance]. de Mey C Med Klin (Munich); 2000 Jan; 95(1):56-62. PubMed ID: 10668347 [No Abstract] [Full Text] [Related]
4. Estimating national drug consumption using data at different points in the pharmaceutical supply chain. Cook MN Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):754-7. PubMed ID: 16989003 [No Abstract] [Full Text] [Related]
5. Postmarketing surveillance and reporting of adverse drug events. Baer RK S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975 [No Abstract] [Full Text] [Related]
6. Commentary by a child psychiatrist in industry on the assessment of drug safety. Allen AJ J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):288-91. PubMed ID: 17630860 [No Abstract] [Full Text] [Related]
7. Ethics of drug trials in India. Kalantri SP Natl Med J India; 2002; 15(3):179. PubMed ID: 12186339 [No Abstract] [Full Text] [Related]
8. Bone marrow purging, 4-hydroperoxycyclophosphamide, and the FDA. Rowley SD J Hematother; 1993; 2(3):289-92. PubMed ID: 7921991 [No Abstract] [Full Text] [Related]
10. [A round table on the methodology of clinical trials. From the design to the meeting of the Oncology Group of the French-speaking members of the Society of Pneumology organized in Brussels 21 September 1990]. Sculier JP; Trillet V; Paesmans M; Markiewicz E; Lebeau B; Dabouis G; Kleisbauer JP Rev Mal Respir; 1992; 9(2):223-6. PubMed ID: 1565837 [No Abstract] [Full Text] [Related]
11. Roche continues to drag its feet on access to Tamiflu data. Gøtzsche PC BMJ; 2013 May; 346():f3001. PubMed ID: 23678077 [No Abstract] [Full Text] [Related]
12. EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents. Schwartsmann G; Wanders J; Koier IJ; Franklin HR; Dalesio O; Hornstra HW; van Glabbeke M; Renard J; Van Oosterom AT; Kaye SB Eur J Cancer; 1991; 27(9):1162-8. PubMed ID: 1835630 [No Abstract] [Full Text] [Related]
14. [Responsibility of the pharmaceutical industry toward the first undesirable effects of new products]. Juillet Y; de Cremiers F Therapie; 1988; 43(5):385-8. PubMed ID: 3227498 [No Abstract] [Full Text] [Related]
15. Beyond pharmacoepidemiology: the larger role of epidemiology in drug development. Guess HA; Stephenson WP; Sacks ST; Gardner JS J Clin Epidemiol; 1988; 41(10):995-6. PubMed ID: 3057118 [No Abstract] [Full Text] [Related]